Word

AMT

Status

Dead

Status Code

710

Status Date

Friday, April 6, 2018

Serial Number

85021857

Registration Number

4017988

Registration Date

Tuesday, August 30, 2011

Mark Type

4000

Filing Date

Friday, April 23, 2010

Published for Opposition

Tuesday, June 14, 2011

Cancellation Date

Friday, April 6, 2018

Trademark Owner History

Amsterdam Molecular Therapeutics (AMT) IP B.V. - Original Registrant

Classifications

1 Nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cell transformed by viral vectors, gene therapy vectors and nucleic acid delivery vectors for other than medical and veterinary purposes; chemical reagents for scientific or research use, namely, nucleic acids and vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes

5 Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and call therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders, single gene disorders and cancers; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers

42 Laboratory research in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry; product development and consultancy in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry

AMERDAM MOLECULAR THERAPEUTICS

Trademark Events

Apr 6, 2018

Cancelled Sec. 8 (6-Yr)

Aug 30, 2011

Registered-Principal Register

Jun 14, 2011

Official Gazette Publication Confirmation E-Mailed

Jun 14, 2011

Published For Opposition

May 7, 2011

Law Office Publication Review Completed

May 2, 2011

Approved For Pub - Principal Register

Apr 13, 2011

Teas/Email Correspondence Entered

Apr 13, 2011

Correspondence Received In Law Office

Apr 13, 2011

Teas Response To Office Action Received

Feb 3, 2011

Notification Of Non-Final Action E-Mailed

Feb 3, 2011

Non-Final Action E-Mailed

Feb 3, 2011

Non-Final Action Written

Jan 11, 2011

Teas/Email Correspondence Entered

Jan 11, 2011

Correspondence Received In Law Office

Jan 11, 2011

Assigned To Lie

Dec 21, 2010

Teas Response To Office Action Received

Jun 22, 2010

Notification Of Non-Final Action E-Mailed

Jun 22, 2010

Non-Final Action E-Mailed

Jun 22, 2010

Non-Final Action Written

Jun 22, 2010

Assigned To Examiner

May 1, 2010

Notice Of Pseudo Mark Mailed

Apr 30, 2010

New Application Office Supplied Data Entered In Tram

Apr 27, 2010

New Application Entered In Tram